Home

Our Approach

Our proprietary, highly targeted antibody drug conjugates (ADCs) are armed with highly potent pyrrolobenzodiazepine (PBD)-based warheads to selectively kill cancer cells.

Learn More ButtonLearn More Button

Pipeline

The selective targeting and unique mechanism of action of our ADCs enables the potential for our robust pipeline of therapies to have enhanced, durable efficacy and limited side effects in patients.

View Pipeline ButtonPipeline View Button

Clinical Trials

We are advancing our ADCs through clinical trials in multiple hematological and solid tumor indications, including a pivotal Phase II trial of ADCT-402 (loncastuximab tesirine) in patients with relapsed or refractory diffuse large B-cell lymphoma.

Find Out More ButtonFind Out More Button

News

ADC Therapeutics Doses First Patients in Pivotal Phase 2 Clinical Trial of ADCT-301 in Patients with Relapsed or Refractory Hodgkin Lymphoma

ADC Therapeutics Doses First Patients in Pivotal Phase 2 Clinical Trial of ADCT-301 in Patients with Relapsed or Refractory Hodgkin Lymphoma
Trial to support anticipated BLA submission in 1H 2022   Lausanne, Switzerland, October 17, 2019 – ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent and targeted antibody drug conjugates (ADCs) for patients suffering from hematological malignancies and solid tumors, today announced that the first patients have been dosed in

ADC Therapeutics Announces Withdrawal of Registration Statement

ADC Therapeutics Announces Withdrawal of Registration Statement
Lausanne, Switzerland, October 2, 2019 – ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent and targeted antibody drug conjugates (ADCs) for patients suffering from hematological malignancies and solid tumors, today announced that it has withdrawn its registration statement on Form F-1 with the U.S. Securities and Exchange Commission related

ADC Therapeutics Announces Launch of Initial Public Offering

ADC Therapeutics Announces Launch of Initial Public Offering
Lausanne, Switzerland — September 23, 2019 — ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent and targeted antibody drug conjugates for patients suffering from hematological malignancies and solid tumors, announced today that it has launched the initial public offering of 8,164,000 shares of its common shares. In addition, ADC Therapeutics has